Jun 24, 2020 / 05:30PM GMT
Tazeen Ahmad - BofA Merrill Lynch, Research Division - VP
Good afternoon, everybody. Thanks for joining us. I am Tazeen Ahmad. I'm one of the senior biotech analyst here at Bank of America. Welcome to our virtual Napa conference. As part of this afternoon's session, it's my pleasure to introduce our presenting company, Alnylam. Presenting for Alnylam for the next 50 minutes or so will be CEO, John Maraganore. John, good afternoon. Thank you for joining us.
John M. Maraganore - Alnylam Pharmaceuticals, Inc. - CEO & Executive Director
Thanks, Tazeen. Good afternoon to you and to everybody, and thanks for inviting us.
Questions and Answers:
Tazeen Ahmad - BofA Merrill Lynch, Research Division - VPSo most people already know the story of Alnylam. And normally, we ask people to give a couple of minute intro. But I think given the audience that we have filed in, I think it makes more sense probably just to dive in to some questions. And so I thought maybe we could talk to you initially about COVID. On your 1Q
Trustpilot
